Medicamento autorizado
Un regulador lo ha autorizado para al menos un uso, en al menos un país. Eso no dice nada sobre usos fuera de la licencia.
Esta página es un esbozo
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
Qué tan sólida es la evidencia
Hasta dónde ha llegado
Todo medicamento sube la misma escalera. La mayoría de los compuestos nunca llega a lo más alto, y el lugar que ocupa indica cuánto pueden sostener sus afirmaciones.
- Medicamento autorizado: Semaglutide
Un regulador ha revisado los ensayos y lo ha autorizado para un uso concreto.
- Fase 3
Ensayos aleatorizados grandes, a menudo con miles de personas, frente a placebo o un tratamiento estándar.
- Fase 2
Ensayos de tamaño medio que miden la dosis frente al efecto en personas con la enfermedad.
- Fase 1 y estudios humanos iniciales
Primeros estudios en personas: seguridad y cómo el organismo lo procesa.
- Células y animales
Trabajo de laboratorio y con animales. Un resultado en animales no es un resultado en personas.
- 3,032
- artículos en PubMed
- 1,556
- de ellos en personas
- 271
- ensayos aleatorizados
- 402
- revisiones
Un recuento indica cuánto se ha publicado, no lo que encontró. Contado en PubMed: 2026-11-16
Manipulación y reconstitución
Del polvo a una muestra medida
Los mismos cuatro pasos para cualquier vial liofilizado. Manipulación de laboratorio, no uso en una persona.
1. Lea el vial
La etiqueta indica la masa de péptido en el vial, en miligramos. Ese número es el punto de partida de todo cálculo.
2. Añada el diluyente
Se añade un volumen medido de diluyente lentamente, por la pared del vidrio. Haga girar con suavidad; agitar puede dañar un péptido.
3. Calcule la concentración
La concentración es la masa dividida por el volumen: 10 mg en 2 mL son 5 mg por mL.
4. Mida la muestra
El volumen es la masa deseada dividida por la concentración. En una jeringa U-100, 1 mL equivale a 100 unidades.
La calculadora de abajo hace la aritmética y muestra el procedimiento.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Semaglutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Semaglutide; no amount here is a recommendation.
Semaglutide: en PubMed
What PubMed held for Semaglutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 3,032
- papers
- 1,556
- in humans
- 300
- clinical trials
- 271
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Meta-analysisTan HC, Dampil OA, Marquez MM Journal of the ASEAN Federation of Endocrine Societies, 2022. PMID 36578889
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Randomized trialWilding JPH, Batterham RL, Davies M, et al. Diabetes, obesity & metabolism, 2022. PMID 35441470
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Randomized trialWilding JPH, Batterham RL, Calanna S, et al. The New England journal of medicine, 2021. PMID 33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Randomized trialLincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine, 2023. PMID 37952131
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
TrialAronne LJ, Horn DB, le Roux CW, et al. The New England journal of medicine, 2025. PMID 40353578
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Randomized trialRubino D, Abrahamsson N, Davies M, et al. JAMA, 2021. PMID 33755728
- Safety of Semaglutide
ReviewSmits MM, Van Raalte DH Frontiers in endocrinology, 2021. PMID 34305810
- Semaglutide for the treatment of obesity
ReviewChao AM, Tronieri JS, Amaro A, et al. Trends in cardiovascular medicine, 2023. PMID 34942372
Search used: ("Semaglutide"[ti]). Run it on PubMed
Enlaces de investigación
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Semaglutide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.
Also in Metabolic
Sold in blends: Cagrilintide + Semaglutide